by barry101 | Apr 18, 2023 | Press Releases
Sponsored research data presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023 Annamycin demonstrated increased penetration and accumulation in the liver, which correlated with high antitumor activity in HEPA 1-6...
by barry101 | Mar 23, 2023 | Press Releases
– 2022 marked by continued execution and growing body of positive data across clinical and preclinical development programs – Sufficient capital to fund operations into the third quarter of 2024 – Company to host conference call and webcast today at...
by barry101 | Mar 22, 2023 | Press Releases
– Actively recruiting in three Phase 1b/2 clinical trials (with one now in Phase 2) and have recently concluded one trial – Reached 50% recruitment of Phase 2 portion of soft tissue sarcoma (STS) lung metastases trial – Multiple expected milestones...
by barry101 | Mar 21, 2023 | Press Releases
HOUSTON, March 21, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses,...
by barry101 | Mar 15, 2023 | Press Releases
HOUSTON, March 15, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses,...
